emselex
pharmaand gmbh - darifenacine hydrobromide - urinary incontinence, urge; urinary bladder, overactive - urologicals, geneesmiddelen voor urinaire frequentie en incontinentie - symptomatische behandeling van urge-incontinentie en / of verhoogde urinaire frequentie en urgentie zoals die kunnen optreden bij volwassen patiënten met het overactieve blaassyndroom.
yervoy
bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastische middelen - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4. yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 en 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.
kymriah
novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andere antineoplastische middelen - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.
ozalin 2 mg/ml drank in verpakking voor eenmalig gebruik
primex pharmaceuticals oy mariankatu 21 c 00170 helsinki (finland) - midazolam 2 mg/ml - drank - citroenzuur 1-water (e 330) ; cyclodextrine, gamma ; ethanol ; natriumhydroxide (e 524) ; sinaasappelsmaakstof ; sucralose (e 955) ; tocoferol, dl-alfa acetaat ; water voor injectie ; water, gezuiverd, citroenzuur 1-water (e 330) ; cyclodextrine, gamma ; natriumhydroxide (e 524) ; sinaasappelsmaakstof ; sucralose (e 955) ; tocoferol, dl-alfa acetaat ; water voor injectie - midazolam
yttrium (y-90) citraat 37 mbq/ml - 370 mbq/ml inj. susp. i.artic. flac.
cis bio international - yttrium(y-90)citraat 37 mbq/ml - 370 mbq/ml - suspensie voor injectie - 37-370 mbq/ml - yttrium(y-90)citraat - yttrium (90y) citrate colloid
fixaprost 50 µg/ml - 5 mg/ml oogdruppels opl. verp. éénmalig gebr.
laboratoires théa - timololmaleaat 6,83 mg/ml - eq. timolol 5 mg/ml; latanoprost 0,05 mg/ml - oogdruppels, oplossing in verpakking voor éénmalig gebruik - 50 µg/ml - 5 mg/ml - latanoprost 0.05 mg/ml; timololmaleaat 6.83 mg/ml - timolol, combinations
lutenyl 5 mg tabl.
theramex ireland ltd. - nomegestrolacetaat 5 mg - tablet - 5 mg - nomegestrolacetaat 5 mg - nomegestrol
ofloxacine ntc 3 mg/ml oogdruppels opl. verp. éénmalig gebr.
novelty. technology. care s.r.l. - ofloxacine 3 mg/ml - oogdruppels, oplossing in verpakking voor éénmalig gebruik - 3 mg/ml - ofloxacine 3 mg/ml - ofloxacin
quetiapin sandoz 100 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 115,13 mg - eq. quetiapine 100 mg - filmomhulde tablet - 100 mg - quetiapinefumaraat 115.13 mg - quetiapine
quetiapin sandoz 25 mg filmomh. tabl.
sandoz sa-nv - quetiapinefumaraat 28,78 mg - eq. quetiapine 25 mg - filmomhulde tablet - 25 mg - quetiapinefumaraat 28.78 mg - quetiapine